NCT06327685View on ClinicalTrials.gov

Avapritinib With Decitabine in Patients With SM-AHN

PHASE1RecruitingINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

March 13, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2027

Conditions
Systemic Mastocytosis With an Associated Hematologic Neoplasm
Interventions
DRUG

Avapritinib

Avapritinib is an oral tyrosine kinase inhibitor.

DRUG

Decitabine

Decitabine is a nucleoside metabolic inhibitor given intravenously.

COMBINATION_PRODUCT

Decitabine/Cedazuridine

Decitabine/Cedazuridine is a combination medicine given orally.

Trial Locations (7)

10065

NOT_YET_RECRUITING

Memorial Sloan Kettering Cancer Center, New York

33612

RECRUITING

Moffitt Cancer Center, Tampa

48109

NOT_YET_RECRUITING

University of Michigan, Ann Arbor

84132

NOT_YET_RECRUITING

University of Utah Health, Salt Lake City

85054

NOT_YET_RECRUITING

Mayo Clinic - Arizona, Phoenix

94305

NOT_YET_RECRUITING

Stanford University Medical Center, Palo Alto

02215

NOT_YET_RECRUITING

Dana-Farber Cancer Institute, Boston

Sponsors
All Listed Sponsors
collaborator

Blueprint Medicines Corporation

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER

NCT06327685 - Avapritinib With Decitabine in Patients With SM-AHN | Biotech Hunter | Biotech Hunter